- Home
- NBTX vs LRMR Comparison
NBTX vs LRMR Comparison
Compare NBTX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- LRMR
- Stock Information
- Founded
- NBTX 2003
- LRMR N/A
- Country
- NBTX France
- LRMR United States
- Employees
- NBTX N/A
- LRMR N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- LRMR Health Care
- Exchange
- NBTX Nasdaq
- LRMR Nasdaq
- Market Cap
- NBTX 167.8M
- LRMR 183.8M
- IPO Year
- NBTX 2020
- LRMR N/A
- Fundamental
- Price
- NBTX $4.10
- LRMR $2.25
- Analyst Decision
- NBTX Strong Buy
- LRMR Strong Buy
- Analyst Count
- NBTX 1
- LRMR 8
- Target Price
- NBTX $8.00
- LRMR $19.63
- AVG Volume (30 Days)
- NBTX 11.5K
- LRMR 1.3M
- Earning Date
- NBTX 04-02-2025
- LRMR 04-30-2025
- Dividend Yield
- NBTX N/A
- LRMR N/A
- EPS Growth
- NBTX N/A
- LRMR N/A
- EPS
- NBTX N/A
- LRMR N/A
- Revenue
- NBTX N/A
- LRMR N/A
- Revenue This Year
- NBTX N/A
- LRMR N/A
- Revenue Next Year
- NBTX $221.06
- LRMR N/A
- P/E Ratio
- NBTX N/A
- LRMR N/A
- Revenue Growth
- NBTX N/A
- LRMR N/A
- 52 Week Low
- NBTX $2.76
- LRMR $1.61
- 52 Week High
- NBTX $7.29
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- NBTX 64.63
- LRMR 54.28
- Support Level
- NBTX $3.64
- LRMR $1.80
- Resistance Level
- NBTX $4.20
- LRMR $2.33
- Average True Range (ATR)
- NBTX 0.16
- LRMR 0.19
- MACD
- NBTX 0.04
- LRMR 0.03
- Stochastic Oscillator
- NBTX 88.51
- LRMR 86.67
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.